Evaluation of the long-term administration of rifaximin for more than three years in the treatment of repeated and recurrent overt hepatic encephalopathy

2Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula, L-carnitine and zinc. After the additional administration of rifaximin (1,200 mg/day orally), his consciousness level was well controlled for 3 years without any adverse effects. The long-term administration of rifaximin may be useful and safe for managing recurrent overt HE, although the maintenance dosage and duration of rifaximin and safety should be evaluated in patients with ameliorated HE.

Cite

CITATION STYLE

APA

Fujiwara, Y., Suzuki, K., Yusa, K., Eizuka, M., Miura, M., Watanabe, Y., … Takikawa, Y. (2021). Evaluation of the long-term administration of rifaximin for more than three years in the treatment of repeated and recurrent overt hepatic encephalopathy. Internal Medicine, 60(7), 1027–1033. https://doi.org/10.2169/INTERNALMEDICINE.5793-20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free